Lumbard & Kellner LLC raised its position in shares of Shire PLC (NASDAQ:SHPG) by 46.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,685 shares of the biopharmaceutical company’s stock after purchasing an additional 8,515 shares during the quarter. Shire accounts for about 2.2% of Lumbard & Kellner LLC’s investment portfolio, making the stock its 15th largest position. Lumbard & Kellner LLC’s holdings in Shire were worth $4,087,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. YorkBridge Wealth Partners LLC lifted its holdings in Shire by 81.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 317 shares in the last quarter. BB&T Investment Services Inc. raised its position in shares of Shire by 1,672.3% during the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 786 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Shire during the second quarter valued at approximately $171,000. Stephens Inc. AR raised its position in shares of Shire by 22.2% during the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares during the last quarter. Finally, Aureus Asset Management LLC bought a new stake in shares of Shire during the second quarter valued at approximately $212,000. 20.27% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently issued reports on SHPG. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the company a “buy” rating in a research report on Tuesday, December 5th. Royal Bank of Canada reiterated a “buy” rating and set a $213.00 price objective on shares of Shire in a research report on Monday, October 2nd. FBR & Co reiterated a “buy” rating and set a $201.00 price objective on shares of Shire in a research report on Monday, October 30th. Liberum Capital upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Finally, ValuEngine upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $212.18.

Shares of Shire PLC (NASDAQ SHPG) opened at $148.50 on Tuesday. Shire PLC has a 1 year low of $137.17 and a 1 year high of $192.15. The firm has a market cap of $44,509.82, a price-to-earnings ratio of 10.18, a P/E/G ratio of 0.82 and a beta of 1.59. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.

Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company had revenue of $3.70 billion for the quarter. During the same quarter in the prior year, the firm posted $3.17 EPS. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. analysts forecast that Shire PLC will post 15 EPS for the current fiscal year.

WARNING: This story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/12/lumbard-kellner-llc-has-4-09-million-holdings-in-shire-plc-shpg.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.